Transfusion-Associated Circulatory Overload (TACO)MANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

492 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp35

Immediate recognition

›TACO presentation pattern

›Acute dyspnea during or within 6-12 hours of blood product transfusion

›New or worsening hypoxemia (SpO2 < 94%)

›Hypertension and widened pulse pressure

›Signs of pulmonary edema: bilateral crackles, orthopnea, frothy sputum

›Stop the transfusion immediately on suspicion

Airway and oxygenation

›Oxygenation priorities

›Supplemental oxygen via nasal cannula or face mask as first step

›High-flow nasal cannula (HFNC) for SpO2 < 90% on standard oxygen

›Non-invasive ventilation (BiPAP/CPAP) for persistent hypoxemia or respiratory distress

›Target SpO2 92-96%

›Avoid NIV if aspiration risk is concurrent

›Intubation and mechanical ventilation for failure of NIV or worsening hypoxemia

›Indication: SpO2 < 88% despite NIV or increasing work of breathing

›Mechanical ventilation in up to 71% of ICU-based TACO cases (Critical Care Medicine, 2018)

Hemodynamic targets

›Hemodynamic monitoring goals

›Continuous pulse oximetry

›Cardiac monitoring for rate and rhythm

›Non-invasive blood pressure every 5 minutes initially

›Arterial line if refractory hypertension or need for frequent ABG

›Strict intake and output with Foley catheter in severe presentations

›Hemodynamic targets

›Systolic blood pressure control (typically elevated in TACO, target < 160 mmHg)

›Heart rate target 60-100 bpm

›Urine output > 0.5 mL/kg/hour as marker of diuretic response

02History/hx50

Temporal relationship to transfusion

›Transfusion timeline

›Onset during transfusion or within 6-12 hours of completion

›Number of units transfused and product type (RBC, FFP, platelets, cryoprecipitate)

›Rate of infusion and total volume infused

›Concurrent IV fluid administration during transfusion

Symptoms

›Respiratory symptoms

›Acute dyspnea (cardinal feature)

›Orthopnea

›Paroxysmal nocturnal dyspnea

›Cough, productive or with frothy/pink sputum

›Cardiovascular symptoms

›Chest tightness or pressure

›Palpitations

›Lower extremity edema

›Weight gain over preceding days

›Key negative findings suggesting alternative diagnosis

›Fever absent in TACO (present in TRALI, septic reaction, hemolytic reaction)

›Rigors, urticaria, flank pain, dark urine absent in TACO

Risk factors

›Patient-level risk factors (independent predictors from multivariable analyses)

›Age > 70 years

›Congestive heart failure or reduced ejection fraction

›Chronic kidney disease or ESRD, especially dialysis-dependent

›Positive fluid balance in preceding 24 hours

›Small body habitus or low body weight

›Deep pre-transfusion anemia (very low baseline hemoglobin)

03Physical Exam/exam27

Vital signs

›Vital sign pattern in TACO

›Hypertension (distinguishing feature from TRALI)

›Widened pulse pressure

›Tachycardia

›Tachypnea

›Hypoxemia: SpO2 < 94% on room air

›Temperature typically normal (fever suggests alternative diagnosis)

Respiratory examination

›Pulmonary findings

›Bilateral crackles/rales (most sensitive finding)

›Decreased breath sounds at lung bases (pleural effusions)

›Increased work of breathing: accessory muscle use, intercostal retractions

›Orthopnea on lying flat

›Frothy pink sputum in severe cases

Cardiovascular examination

›Cardiac signs of volume overload

›Elevated jugular venous pressure (JVP)

›S3 gallop

›Peripheral pitting edema

›Diaphoresis

›Signs requiring urgent escalation

›Cyanosis

›Severe respiratory distress with inability to speak in full sentences

›Hemodynamic instability (hypotension suggests TRALI or septic reaction rather than TACO)

Key examination pitfalls

›Exam pitfalls

›Hypotension in presumed TACO should trigger reassessment for TRALI or septic transfusion reaction

04Differential Diagnosis/ddx35

Life-threatening mimics requiring urgent distinction

›Transfusion-Related Acute Lung Injury (TRALI)

›ICD-10: J70.2

›Noncardiogenic (permeability) pulmonary edema

›Key distinguishing features: hypotension or normotension, normal/low BNP, fever, no diuretic response

›Onset within 6 hours of transfusion (shorter window than TACO)

›Treatment differs: avoid diuretics, supportive oxygen/ventilation

›Septic transfusion reaction

›ICD-10: T80.29XA

›Fever, rigors, hypotension, tachycardia

›Blood cultures from patient and transfused product

›Bacterial contamination most common with platelet products

›Acute hemolytic transfusion reaction

›ICD-10: T80.910A

›Fever, flank pain, dark urine, hemoglobinemia, hemoglobinuria

›ABO incompatibility most severe form

›Anaphylactic transfusion reaction

›ICD-10: T80.59XA

›Urticaria, angioedema, bronchospasm, hypotension

›IgA deficiency with anti-IgA antibodies a classic mechanism

Cardiac and pulmonary differentials

›Acute decompensated heart failure (non-transfusion-related)

›ICD-10: I50.9

›May be indistinguishable; temporal relationship to transfusion is the key clue

›Pulmonary embolism

›ICD-10: I26.99

›Pleuritic chest pain, unilateral leg swelling, hemoptysis

›SpO2 may be low but exam typically without bilateral crackles

05Laboratory Tests/lt33

Biomarkers for TACO diagnosis

›BNP and NT-proBNP (primary diagnostic biomarker for TACO)

›Post/pre-transfusion NT-proBNP ratio > 1.5 supports TACO diagnosis

›Post-transfusion BNP < 300 pg/mL makes TACO unlikely

›Post-transfusion NT-proBNP < 2000 pg/mL makes TACO unlikely

›Specificity reduced in critically ill patients (Transfusion, 2019)

›Collect pre-transfusion sample when TACO risk is anticipated in high-risk patients

Arterial blood gas

›ABG interpretation in TACO

›Hypoxemia: PaO2 < 60 mmHg

›May show respiratory alkalosis early

›Mixed acid-base disorder in severe or prolonged presentations

›PaO2/FiO2 ratio < 300 consistent with significant pulmonary edema

Hematology and chemistry

›Complete blood count

›Verify hemoglobin response to transfusion

›Leukocytosis suggests infection (septic reaction or concurrent process)

›Basic metabolic panel

›Renal function to guide diuretic dosing

›Electrolytes (hypokalemia risk with loop diuretics)

›Troponin

›Elevated troponin if ACS precipitating decompensation

›Demand ischemia from hypoxemia may elevate troponin

›Lactate

›If hemodynamic compromise or shock physiology

›Blood cultures

›If fever present to rule out septic transfusion reaction

›Cultures from both patient and implicated blood product bag

06Diagnostic Tests/dt53

Scoring Systems

›TACO diagnostic criteria (International Surveillance Definition, Lancet Haematology, 2019)

›Acute or worsening respiratory distress during or within 12 hours of transfusion

›Evidence of new or worsening pulmonary edema on imaging

›Evidence of cardiovascular system involvement (at least one of):

›Elevated BNP or NT-proBNP

›New or worsening hypertension

›New or worsening tachycardia

›Evidence of left heart failure

›Positive fluid balance

›Symptoms improve with diuresis (supportive but not required)

›TACO severity stratification

›Mild: supplemental oxygen only, rapid diuretic response

›Moderate: HFNC or NIV required

›Severe: mechanical ventilation required (occurs in up to 71% of ICU TACO, Critical Care Medicine, 2018)

›TACO vs TRALI differentiation scoring

›Hypertension: favors TACO

›Hypotension: favors TRALI

›NT-proBNP ratio > 1.5: favors TACO

›Normal BNP with bilateral infiltrates: favors TRALI

›Response to diuretics: favors TACO

MRI

›MRI in TACO

›Not indicated as first-line investigation in acute TACO

›Cardiac MRI may be used in follow-up to characterize underlying cardiomyopathy

›Cardiac MRI indications post-TACO: new reduced EF on echo, unexplained LV dysfunction

›Not appropriate in acute hemodynamic instability

07Disposition/dispo33

ICU admission indications

›ICU-level care criteria

›Mechanical ventilation required

›NIV failure or rapid progression requiring intubation

›Hemodynamic instability

›Refractory hypoxemia despite maximal non-invasive support

›Ongoing diagnostic uncertainty with high severity presentation

Hospital ward admission indications

›Ward admission criteria

›Supplemental oxygen requirement beyond baseline

›Incomplete response to initial diuresis

›Significant underlying cardiac or renal disease requiring monitoring

›Uncertain diagnosis (TACO vs TRALI requires observation)

›Ongoing hypoxemia after initial treatment

Observation and discharge criteria

›Observation unit appropriateness

›Mild TACO with rapid complete response to one dose of furosemide

›Return to baseline oxygenation within 4-6 hours

›Hemodynamically stable throughout

›Discharge criteria

›Complete symptom resolution

›Return to baseline oxygenation on room air or baseline supplemental oxygen

›Stable hemodynamics

›Adequate urine output achieved

›Patient and family educated on TACO recurrence risk and prevention

Mandatory consults and reporting

›Blood bank / transfusion medicine consultation

›Mandatory for all suspected TACO (hemovigilance reporting requirement)

08Treatment/t58

Immediate transfusion management

›Stop the transfusion

›Immediate cessation of the implicated blood product is the first intervention

›Maintain IV access with normal saline at keep-open rate

›Notify blood bank immediately

›Retain blood product bag, tubing, and blood samples for investigation

Oxygen and ventilatory support

›Supplemental oxygen

›Nasal cannula 2-6 L/min for mild hypoxemia

›Non-rebreather mask for SpO2 < 90% not responding to nasal cannula

›Target SpO2 92-96%

›Non-invasive ventilation

›BiPAP or CPAP for persistent hypoxemia or respiratory distress despite oxygen

›Starting settings: CPAP 5-10 cmH2O or BiPAP IPAP 10-14 / EPAP 5-8 cmH2O

›Titrate to achieve SpO2 > 92% and reduction in work of breathing

›Mechanical ventilation

›Intubation for NIV failure or rapidly worsening hypoxemia

›Lung-protective ventilation: tidal volume 6 mL/kg ideal body weight

›PEEP 5-10 cmH2O initially, titrate to oxygenation

Diuretic therapy

›Furosemide (first-line diuretic, both diagnostic and therapeutic)

›Furosemide 20-40 mg IV in furosemide-naive patients

›Assess response at 30-60 minutes

›Repeat dose if insufficient diuresis

›In patients on chronic diuretics: dose equivalent to or greater than home dose

›If on oral furosemide 40 mg daily, give furosemide 40-80 mg IV

›Target urine output: 500-1000 mL over 2-4 hours

›Strict intake and output monitoring

09Special Populations/sp55

Pregnancy

›TACO in pregnancy

›Physiologic changes increasing TACO risk

›Plasma volume expansion 40-50% increases cardiac preload

›Reduced oncotic pressure in pregnancy

›Pre-eclampsia with hypertension and capillary leak increases risk

›Obstetric transfusion indications with TACO risk

›Postpartum hemorrhage (most common indication for blood transfusion in obstetrics)

›Peripartum cardiomyopathy combined with transfusion is high-risk combination

›Management considerations in pregnancy

›Furosemide generally safe in pregnancy (category C); use lowest effective dose

›Fetal monitoring during diuresis: watch for fetal heart rate changes with maternal hemodynamic shifts

›Upright positioning and oxygen as first steps

›Obstetrics and maternal-fetal medicine consultation for severe cases

›Strict fluid balance monitoring given physiologic changes

›Prevention in high-risk obstetric patients

›Single-unit strategy and reassessment between units

›Pre-transfusion furosemide 20 mg IV in high-risk obstetric patients

Geriatric

›TACO in older adults (age > 70 years is independent risk factor)

›Physiologic changes increasing risk

›Reduced cardiac reserve and diastolic dysfunction

›Reduced renal clearance limiting ability to handle volume loads

›High prevalence of baseline CHF, CKD, and hypertension

›Polypharmacy including diuretics and antihypertensives

›Clinical presentation differences

›May present with altered mental status as predominant feature (hypoxemia effect)

›Orthopnea may be underreported in non-communicative patients

10Background/b51

Epidemiology

›Incidence and burden

›TACO affects approximately 1-12% of at-risk transfused patients (Transfusion Medicine Reviews, 2019)

›Leading cause of transfusion-related morbidity and mortality worldwide

›Widely underrecognized and underreported; true incidence likely higher than surveillance data

›Up to 50% of cases occur after transfusion of a single unit (Blood Reviews, 2022)

›Outcomes data

›In-hospital mortality approximately 21% in TACO cases vs 11% in matched controls

›Cases requiring ICU mechanical ventilation account for up to 71% of ICU TACO presentations (Critical Care Medicine, 2018)

›Full resolution typically within 24-48 hours with appropriate treatment

›Population-level risk

›Age > 70 years is an independent risk factor

›CHF and CKD dramatically increase risk

›Plasma transfusion (especially in females) carries higher TACO risk than RBC transfusion

Pathophysiology

›Two-hit model of TACO pathogenesis (Blood Reviews, 2022)

›First hit: patient comorbidity rendering volume non-compliant

›Reduced left ventricular compliance (diastolic or systolic dysfunction)

›Reduced renal clearance of excess volume

›Positive fluid balance before transfusion

›Second hit: the transfusion itself

›Volume loading exceeding cardiac and renal reserve

›Colloid osmotic effects of blood products

›Pro-inflammatory mediators from stored blood products

›Storage lesion byproducts contributing to endothelial effects

›Mechanism of pulmonary edema

›Hydrostatic (cardiogenic) pulmonary edema

›Elevated left-sided filling pressures from volume overload

11Patient Discharge Instructions/pdi34

copy discharge instructions

›What happened to you

›You had a reaction to a blood transfusion called TACO (Transfusion-Associated Circulatory Overload)

›This reaction caused fluid to build up in your lungs, making it hard to breathe

›TACO happens when the heart temporarily cannot handle the extra fluid from the transfusion

›You were treated with oxygen and a water pill (diuretic) to remove the extra fluid

›What to expect at home

›Most people feel much better within 24-48 hours after treatment

›You may notice increased urination for several hours after your diuretic treatment

›Mild fatigue is normal after this reaction

›Do not restrict fluids excessively at home unless specifically instructed

›Your medications

›Take all prescribed medications as directed

›If you were prescribed a diuretic (water pill), take it at the same time each day

›Do not stop your heart or kidney medications without speaking to your doctor

›Weigh yourself every morning and call your doctor if you gain more than 1-2 kg in 24 hours

›Future transfusions

›Tell every healthcare provider about your history of TACO before any future transfusion

›Your chart has been flagged so future transfusions will be given more slowly

›You may receive a diuretic before future transfusions to prevent recurrence

›Your blood bank has been notified about this reaction

›Return to the emergency department immediately for

›Difficulty breathing or shortness of breath

›Chest pain or chest tightness

›New or worsening cough

›Feeling your heart racing or pounding

›Swelling in your legs or feet that is getting worse

›Coughing up pink or frothy sputum

12References/r28

Guidelines and key sources

›Semple JW, Rebetz J, Kapur R. Transfusion-Associated Circulatory Overload and Transfusion-Related Acute Lung Injury. Blood. 2019. PMID: 30808638

›Comprehensive review of TACO and TRALI mechanisms, differentiation, and management

›Bosboom JJ, Klanderman RB, Migdady Y, et al. Transfusion-Associated Circulatory Overload: A Clinical Perspective. Transfusion Medicine Reviews. 2019. PMID: 30853167

›Clinical perspective including incidence 1-12% in at-risk populations

›Delaney M, Wendel S, Bercovitz RS, et al. Transfusion Reactions: Prevention, Diagnosis, and Treatment. Lancet. 2016. PMID: 27083327

›Comprehensive review of transfusion reactions including TACO management

›Bulle EB, Klanderman RB, Pendergrast J, et al. The Recipe for TACO: Pathophysiology and Mitigation Strategies. Blood Reviews. 2022. PMID: 34627651

›Two-hit model of TACO pathogenesis; 50% of cases after single unit

›Wiersum-Osselton JC, Whitaker B, Grey S, et al. Revised International Surveillance Case Definition of TACO. Lancet Haematology. 2019. PMID: 31080132

›Current international consensus diagnostic criteria for TACO

›Roubinian NH, Hendrickson JE, Triulzi DJ, et al. Contemporary Risk Factors and Outcomes of TACO. Critical Care Medicine. 2018. PMID: 29300236

›Risk factor analysis; 21% mortality vs 11% matched controls; 71% ICU intubation rate

›Sarai M, Tejani AM. Loop Diuretics for Patients Receiving Blood Transfusions. Cochrane Database of Systematic Reviews. 2015

›Systematic review supporting prophylactic loop diuretics in at-risk transfusion recipients

›Klanderman RB, Bosboom JJ, Migdady Y, et al. TACO - A Systematic Review of Diagnostic Biomarkers. Transfusion. 2019. PMID: 30488959

›NT-proBNP ratio > 1.5, post-transfusion BNP thresholds

›Alam A, Lin Y, Lima A, Hansen M, Callum JL. The Prevention of Transfusion-Associated Circulatory Overload. Transfusion Medicine Reviews. 2013. PMID: 23465703

›Prevention strategies including pre-transfusion diuretics and single-unit strategy

›Carson JL, Triulzi DJ, Ness PM. Indications for and Adverse Effects of Red-Cell Transfusion. NEJM. 2017. PMID: 28121507

›Restrictive transfusion thresholds; TACO as major adverse effect

›Gajic O, Gropper MA, Hubmayr RD. Pulmonary Edema After Transfusion: How to Differentiate TACO From TRALI. Critical Care Medicine. 2006. PMID: 16617253

›Fluid protein/serum protein ratio < 0.65 for TACO, > 0.75 for TRALI

›Vlaar APJ, Zwaginga JJ, Wiersum-Osselton JC. How I Diagnose and Treat Cardiorespiratory Complications of Transfusion. Blood. 2025. PMID: 39374519

›Contemporary approach to cardiorespiratory transfusion reactions

›Lowack J, Vlaar AP, Klanderman RB, Peters AL. Pulmonary Transfusion Reactions as an Immunological Spectrum Disorder. Current Opinion in Immunology. 2025. PMID: 41202391

›TACO/TRALI overlap as spectrum disorder

›Goel R, Tobian AAR, Shaz BH. Noninfectious Transfusion-Associated Adverse Events and Their Mitigation Strategies. Blood. 2019. PMID: 30808635

Learn More: Transfusion-Associated Circulatory Overload (TACO)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.